{
    "nctId": "NCT01993576",
    "briefTitle": "ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.",
    "officialTitle": "Histological Study of the (Intravenously Injected) ICG Distribution in Tumor Bearing Breasts and in Axillary Pieces of Dissection.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer.",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Study of the evantual difference of indocyanine in mammalian tissue in patients mastocmemezied for breast canrcinoma.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histopathological diagnosis of breast cancer for which a mastectomy with axillary dissection is planned.\n* Informed Consent signed.\n\nExclusion Criteria:\n\n* Diagnosis of breast cancer established by lumpectomy or \"macro-biopsy\".\n* Operation after neo-adjuvant chemotherapy,\n* Age less than 18 years.\n* For pre-menopausal women, an operation planned for the second phase of their cycle.\n* Inability to give informed consent.\n* History of allergy or hypersensitivity to the investigational product, iodine.\n* Clinical or biological hyperthyroidism.\n* Known \"toxic\" thyroid nodules or known autonomous (hyperfunctional) thyroid.\n* A reported pathological coronary artery disease.\n* Creatinine \\> 1.5 mg / dl.\n* During the 2 weeks before surgery, being on medications which are known to interfere with the ICG (ie anticonvulsants, heparin and haloperidol).\n* Pregnancy or breast feeding period.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}